AU2022397653A1 - Pharmaceutical composition and use thereof - Google Patents

Pharmaceutical composition and use thereof Download PDF

Info

Publication number
AU2022397653A1
AU2022397653A1 AU2022397653A AU2022397653A AU2022397653A1 AU 2022397653 A1 AU2022397653 A1 AU 2022397653A1 AU 2022397653 A AU2022397653 A AU 2022397653A AU 2022397653 A AU2022397653 A AU 2022397653A AU 2022397653 A1 AU2022397653 A1 AU 2022397653A1
Authority
AU
Australia
Prior art keywords
furmonertinib
pharmaceutically acceptable
acceptable salt
mutation
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022397653A
Other languages
English (en)
Inventor
Qing Li
Huibing Luo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Pharmaceuticals Inc
Original Assignee
Shanghai Allist Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Inc filed Critical Shanghai Allist Pharmaceuticals Inc
Publication of AU2022397653A1 publication Critical patent/AU2022397653A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022397653A 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof Pending AU2022397653A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111404293.6A CN116159062A (zh) 2021-11-24 2021-11-24 药物组合物及其用途
CN202111404293.6 2021-11-24
PCT/CN2022/133171 WO2023093663A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
AU2022397653A1 true AU2022397653A1 (en) 2024-07-04

Family

ID=86416859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022397653A Pending AU2022397653A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof

Country Status (10)

Country Link
US (1) US20250017927A1 (https=)
EP (1) EP4436580A4 (https=)
JP (1) JP2024539476A (https=)
KR (1) KR20240124921A (https=)
CN (2) CN116159062A (https=)
AU (1) AU2022397653A1 (https=)
CA (1) CA3238480A1 (https=)
IL (1) IL312874A (https=)
MX (1) MX2024006168A (https=)
WO (1) WO2023093663A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116854694B (zh) * 2023-07-04 2024-07-09 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
WO2023035223A1 (zh) * 2021-09-10 2023-03-16 上海艾力斯医药科技股份有限公司 药物组合物及其用途
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
IL312874A (en) 2024-07-01
JP2024539476A (ja) 2024-10-28
CN118678958A (zh) 2024-09-20
KR20240124921A (ko) 2024-08-19
EP4436580A1 (en) 2024-10-02
MX2024006168A (es) 2024-06-11
CA3238480A1 (en) 2023-06-01
US20250017927A1 (en) 2025-01-16
WO2023093663A1 (en) 2023-06-01
CN116159062A (zh) 2023-05-26
EP4436580A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
WO2023035611A1 (en) Pharmaceutical composition and use thereof
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
WO2023093663A1 (en) Pharmaceutical composition and use thereof
AU2020279289B2 (en) Quinoline derivative used for combination treatment of small cell lung cancer
CN112121048A (zh) 用于联合治疗食管癌的喹啉类化合物
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
WO2024061203A1 (en) Pharmaceutical composition and use thereof
US12377089B2 (en) Quinoline derivative used for soft tissue sarcoma combination therapy
EP3973963A1 (en) Quinoline derivatives for treatment of head and neck cancer
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物
CN113750096A (zh) 用于治疗外周t细胞淋巴瘤的喹啉衍生物
HK40116696A (zh) 药物组合物及其用途
HK40110967A (zh) 药物组合物及其用途
HK40072142A (en) Quinoline derivative used for combination treatment of small cell lung cancer
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物